SUMMARY
The research of Dana Erickson, M.D., involves the clinical outcomes of people with pituitary tumors after their treatment. She also studies acromegaly, nonfunctioning pituitary tumors and Cushing disease.
Dr. Erickson collaborates with Mayo Clinical Laboratories to study and implement the newest available assays to evaluate and treat people with pituitary disorders. She studies copeptin, an amino acid peptide, to diagnose water balance disorders. Dr. Erickson also researches the development and application of salivary and hair cortisol levels for the diagnosis of Cushing disease.
Focus areas
- Hair cortisol assay in patients with Cushing disease and nontumoral hypercortisolemia.
- Outcomes of people with craniopharyngiomas and pituitary tumors.
- Improving imaging methods, sometimes using artificial intelligence, for people with pituitary and adrenal disorders.
Significance to patient care
Dr. Erickson's research aims to expedite postoperative pituitary tumor management in terms of water balance disorders. Her studies may benefit and improve diagnosis of Cushing syndrome especially cyclical Cushing syndrome.
Dr. Erickson's research optimizes and follows outcomes after transsphenoidal surgery with regard to acromegaly and postoperative hypopituitarism.
Dr. Erickson strives to expedite medical evaluation and treatment for people with indeterminate adrenal masses. Her research uses precision medicine with the help of artificial intelligence in areas that have images. Precision medicine determines the best treatment for people using their genetic profiles, lifestyles and environment.